- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03718624
A Study of Intraperitoneal and Intravenous Paclitaxel Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells
October 29, 2018 updated by: Qun Zhao, Hebei Medical University
The purpose of this study is to investigate the efficacy and safety of intraperitoneal and intravenous paclitaxel plus apatinib and S-1 in the conversion therapy of gastric cancer with positive exfoliative cancer cells
Study Overview
Status
Unknown
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
36
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Untreated (e.g. chemotherapy, radiotherapy and other antitumor therapy);
- Age:18 to 70 years old;
- Man or female (except pregnant and lactating women);
- Confirmed to gastric adenocarcinoma;
- Proven gastric cancer of T stage was T3 and T4, and no distant metastasis was observed. The exfoliative cancer cells detection in peritoneal washes was positive;
Blood cell count has to meet the following criteria:
WBC≥3.5×109/L; ANC≥1.5×109/L; PLT≥100×109/L; HB≥90g/L;
Liver/kidney function has to meet the following criteria:
ALT and AST≤2.5*ULN TBIL<1.5*ULN; Serum creatinine ≤1.5*ULN;
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;
- Participants were willing to join in this study, good adherence and written informed consent.
Exclusion Criteria:
- Patients with other malignant tumors within 5 years;
- Metastasis was found to be visible to the naked eye;
- It has serious or uncontrolled heart diseases and infections (Including atrial fibrillation, angina pectoris, cardiac insufficiency, ejection fraction less than 50%, poor-controlled hypertension and so on);
- History of psychiatric drugs abuse and can't quit or patients with mental disorders;
- Patients with severe or uncontrollable mental illness;
- Patients with tendency of gastrointestinal bleeding, including the following: a local active ulcerative lesions, and defecate occult blood (+ +).Has melena and hematemesis in two months;
- Pregnant or lactating women;
- It have serious harm to the patient's safety or affect the patients who have completed the research.
- The researchers think inappropriate.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: paclitaxel,apatinib and S-1
|
apatinib:500mg qd po, 28 days is a cycle.
preoperative 2 cycles, 2 cycles after surgery.
Paclitaxel: intraperitoneal paclitaxel 20 mg/m2 and intravenous paclitaxel 50 mg/m2 on days 1 and 8 ,21 days is a cycle.
preoperative 3 cycles, 3 cycles after surgery.
S-1: According to the body surface area, BSA <1.25m2,40mg bid; 1.25m2≤BSA≤1.5m2,50mg
bid; BSA >1.5m2, 60mg bid.
Take the medicine twice daily for 2 weeks, then suspend for 1 week.
preoperative 3 cycles, 3 cycles after surgery.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
R0-resection rate
Time Frame: within 3 weeks after surgery
|
There was no residual by the microscope
|
within 3 weeks after surgery
|
Conversion to negative rate
Time Frame: within 3 weeks after surgery
|
Exfoliative cytology positive gastric cancer conversion to negative rate.
|
within 3 weeks after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival (OS)
Time Frame: 5years
|
Baseline to measured date of death from any cause
|
5years
|
Progression free survival (PFS)
Time Frame: 5years
|
Baseline to measured date of progression or death from any cause
|
5years
|
Adverse events
Time Frame: 5 years
|
Toxicity according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.The number of Participants with adverse events will be recorded at each treatment visit.
|
5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
October 30, 2018
Primary Completion (Anticipated)
October 30, 2019
Study Completion (Anticipated)
October 30, 2020
Study Registration Dates
First Submitted
October 23, 2018
First Submitted That Met QC Criteria
October 23, 2018
First Posted (Actual)
October 24, 2018
Study Record Updates
Last Update Posted (Actual)
October 31, 2018
Last Update Submitted That Met QC Criteria
October 29, 2018
Last Verified
October 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Stomach Diseases
- Stomach Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Protein Kinase Inhibitors
- Paclitaxel
- Apatinib
Other Study ID Numbers
- HRA-G03
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastric Cancer With Positive Exfoliative Cancer Cells
-
Qilu Hospital of Shandong UniversityPeking University People's HospitalCompletedGastric Cancer | Colorectal Cancer | Circulating Tumor CellsChina
-
Amsterdam UMC, location VUmcAstraZenecaRecruitingBreast Cancer | Gastric Cancer | Metastatic Breast Cancer | HER2-positive Breast Cancer | HER2-positive Gastric Cancer | Metastatic Gastric CancerNetherlands
-
Triumvira Immunologics, Inc.Merck Sharp & Dohme LLCTerminatedHER2 Positive Gastric Cancer | Metastatic HER2 Positive Gastroesophageal Junction CancerUnited States, Canada
-
Prof. Wolfgang JanniCompletedHER2-negative Metastatic Breast Cancer | HER2-positive Circulating Tumor CellsGermany
-
AIO-Studien-gGmbHBristol-Myers SquibbCompletedGastric Cancer | Esophageal Cancer | Adenocarcinoma Gastric | Metastatic Gastric Cancer | GastroEsophageal Cancer | HER2 Positive Gastric CancerGermany
-
The First Hospital of Jilin UniversityRecruitingPD-L1 Positive Locally Advanced Patients With Resectable Gastric CancerChina
-
Hospices Civils de LyonRecruitingBreast Cancer | Gastric Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Cancer MetastaticFrance
-
Institut CurieUnknownDuctal Infiltrating Metastatic Breast Cancer | Hormone-receptors Positive Breast CancerFrance
-
Sylvestre KABURACompletedGastric Cancer | Mortality of Gastric Cancer | Overall Survival of Patients With Gastric Cancer
-
Henan Cancer HospitalRongchang Biopharmaceutical; Zhengda Tianqing Pharmaceutical Group Co., Ltd.Not yet recruitingHER2-positive Gastric Cancer | Advanced Gastric CarcinomaChina
Clinical Trials on apatinib
-
Elevar TherapeuticsCompletedAdenoid Cystic CarcinomaUnited States, Korea, Republic of
-
Shanghai Jiao Tong University Affiliated Sixth...UnknownSoft Tissue Sarcoma
-
Peking University Cancer Hospital & InstituteRecruiting
-
Tianjin Medical University Cancer Institute and...Unknown
-
Wuhan Union Hospital, ChinaWithdrawnColorectal Cancer | Chemotherapy | Angiogenesis
-
Tianjin Medical University Second HospitalJiangsu HengRui Medicine Co., Ltd.Unknown
-
The First Affiliated Hospital of Zhengzhou UniversityRecruitingEsophageal Cancer by AJCC V8 StageChina
-
Peking UniversityJiangsu HengRui Medicine Co., Ltd.Recruiting
-
The First Affiliated Hospital of Zhengzhou UniversityRecruiting